title: Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay.
authors.affiliation: Biogen, 14 Cambridge Center, Cambridge, MA, 02142, USA. denise.campagnolo@biogen.com.
authors.forename: Denise
authors.identifier: 0000-0001-5568-5973
authors.initials: D
authors.lastname: Campagnolo
authors.affiliation: Biogen, 14 Cambridge Center, Cambridge, MA, 02142, USA.
authors.forename: Qunming
authors.initials: Q
authors.lastname: Dong
authors.affiliation: Biogen, 14 Cambridge Center, Cambridge, MA, 02142, USA.
authors.forename: Lily
authors.initials: L
authors.lastname: Lee
authors.affiliation: Biogen, 14 Cambridge Center, Cambridge, MA, 02142, USA.
authors.forename: Pei-Ran
authors.initials: PR
authors.lastname: Ho
authors.affiliation: Biogen, 14 Cambridge Center, Cambridge, MA, 02142, USA.
authors.forename: Diogo
authors.initials: D
authors.lastname: Amarante
authors.affiliation: Biogen, 14 Cambridge Center, Cambridge, MA, 02142, USA.
authors.forename: Harold
authors.initials: H
authors.lastname: Koendgen
mesh_terms: D000914:Antibodies, Viral / Q000032:analysis*; D003627:Data Interpretation, Statistical; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D015994:Incidence; D007577:JC Virus; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000453:epidemiology*; D000069442:Natalizumab / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D000914:Antibodies, Viral; D007155:Immunologic Factors; D000069442:Natalizumab